- Home
- HYI vs SLP Comparison
HYI vs SLP Comparison
Compare HYI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYI | SLP |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.7M | 322.4M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | HYI | SLP |
|---|---|---|
| Price | $11.02 | $18.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 50.6K | ★ 427.6K |
| Earning Date | 01-01-0001 | 01-08-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,179,000.00 |
| Revenue This Year | N/A | $2.02 |
| Revenue Next Year | N/A | $6.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.09 |
| 52 Week Low | $10.99 | $12.39 |
| 52 Week High | $12.24 | $37.67 |
Technical Indicators
Market Signals| Indicator | HYI | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 52.89 |
| Support Level | $11.00 | $17.74 |
| Resistance Level | $11.06 | $19.58 |
| Average True Range (ATR) | 0.06 | 0.94 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 11.11 | 35.51 |
Price Performance
Historical ComparisonAbout HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.